Meta-analysis: Non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 5, 2005, Pages 365-372

  Szajewska, H ^a   Mrukowicz, J ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Polish Institute for Evidence Based Medicine   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; PENICILLIN G; PLACEBO; PROBIOTIC AGENT; TETRACYCLINE;

CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COCHRANE LIBRARY; DIARRHEA; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SACCHAROMYCES BOULARDII; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; DIARRHEA; HUMANS; RANDOMIZED CONTROLLED TRIALS; SACCHAROMYCES;

EID: 24344493550     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02624.x     Document Type: Review

References (40)

1. Bartlett JG. Antibiotic-associated diarrhoea. N Engl J Med 2002; 346: 334-9.
2. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin producing clostridia. N Engl J Med 1978; 298: 531-4.
3. Wiström J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47: 43-50.
4. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhoea. Dig Dis 1998; 16: 292-307.
5. Turck D, Bernet JP, Marx J, et al. Incidence and risk factors of oral antibiotic-associated diarrhoea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 2003; 37: 22-6.
6. Elstner CL, Lindsay AN, Book LS, Matsen JM. Lack of relationship of Clostridium difficile to antibiotic-associated diarrhoea in children. Pediatr Infect Dis 1983; 2: 364-6.
7. Barbut F, Meynard JL, Guiguet M, et al. Clostridium difficile-associated diarrhoea in HIV infected patients: epidemiology and risk factors. J Acquir Immune Defic Syndr 1997; 16: 176-81.
8. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. decile-associated diarrhoea in a cohort of hospitalized patients. J Infect Dis 1990; 162: 678-84.
9. Diplock AT, Aggett PJ, Ashwell M, et al. Scientific concepts of functional foods in Europe: consensus document. Br J Nutr 1999; 81 (Suppl. 1): S1-S27.
10. Surawicz CM. Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract Res Clin Gastroenterol 2003; 17: 775-83.
11. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005; 21: 583-90.
12. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. Br Med J 2002; 324: 1361-4.
13. Cremonini F, di Caro S, Nista EC, et al. Meta-analysis: The effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16: 1461-7.
14. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retreival of reports of controlled trials using PubMed. Int J Epidemiol 2002; 31: 150-3.
15. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34.
16. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, for the QUOROM Group. Improving the Quality of Reports of Meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999; 354: 1896-900.
17. Adam J, Barret A, Barret-Bellet C. Essais cliniques contrôlé s en double insu de l'ultra-levure lyophilisée: étude multicentrique par 25 médicins de 388 cas. Gaz Med Fr 1977; 84: 2072-8.
18. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96: 981-8.
19. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998; 36: 171-4.
20. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhoea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90: 439-48.
21. Hotz J. Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii: a prospective study. Z Gastroenterol 1990; 28: 259-60 (German).
22. Surawicz CM, McFarland LV, Elmer G, Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 1989; 84: 1285-7.
23. Potts L, Lewis SJ, Barry R. Randomised double blind placebo controlled study of the ability of Saccharomyces boulardii to prevent antibiotic related diarrhoea [abstract]. Gut 1996; 38 (Suppl. 1): A61.
24. Donat F. Prevention of intestinal side-effects of antibiotics with perenterol. Munch Med Wochenschr 1970; 112: 74-7 (German).
25. Elmer GW, McFarland LV. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother 1987; 31: 129-31.
26. Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 2004; 50: 234-6.
27. Schellenberg D, Bonington A, Champion CM, Lancaster R, Webb S, Main J. Treatment of Clostridium difficile diarrhoea with brewer's yeast. Lancet 1994; 343: 171-2.
28. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Inf Dis 2000; 31: 1012-7.
29. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913-8.
30. Erratum in: JAMA 1994; 272: 518.
31. Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 1993; 16: 419-25.
32. Schellenberg D, Bonningotn A, Champion CM, Lancaster R, Webb S, Main J. Treatment of Clostridium difficile diarrhoea with brewer's yeast. Lancet 1994; 343: 171-2.
33. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104: 1108-15.
34. Wilson KH, Perini I. Role of competition for nutrients in suppression of Clostidium difficile by the colonic microflora. Infect Immun 1988; 56: 2610-4.
35. Qamar A, Aboudola A, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69: 2762-5.
36. Tasteyre A, Bare MC, Karjalainen T, et al. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microbiol Pathogens 2002; 32: 219-25.
37. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with S. boulardii. Am J Med 1998; 105: 71-2.
38. Rijnders BJA, Van Wijngaerden E, Verwaest C, Peetermans WE. Saccharomyces fungemia complicating S. boulardii treatment in a non-immunocompromised host. Intensive Care Med 2000; 26: 825.
39. Zunic P, Lacotte J, Pegoix M, et al. S. boulardii fungemia. Apropos of a case. Therapie 1991; 46: 498-9.
40. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003; 41: 5340-3.